|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||110.02 - 110.02|
|52-week range||110.02 - 110.02|
|Beta (5Y monthly)||1.24|
|PE ratio (TTM)||7.93|
|Earnings date||09 Feb 2022 - 14 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
DaVita's (DVA) work with transplant providers and kidney doctors is likely to slow CKD progression and bolster access to home dialysis and kidney transplantation.
DaVita (DVA) acquires MedSleuth which will help simplify the kidney transplant process and provide patients greater access to transplantation.
In this article we are going to estimate the intrinsic value of DaVita Inc. ( NYSE:DVA ) by taking the forecast future...